Physician profile
Stephen Todd Threadgill
NPI 1225046543
$9,451.20
in general payments reported to CMS, 2019-2025
41 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $543 · 2021: $913 · 2022: $1,215 · 2023: $1,198 · 2024: $1,840 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,379 · Education: $22.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,378.67 |
| Education | $22.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,488.81 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,311.36 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $855.96 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $654.98 | 2019-2025 | |
| Lilly USA, LLC | $561.59 | 2023-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $532.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $394.20 | 2022-2025 | |
| Enterra Medical, INC. | $383.87 | 2023-2025 | |
| Daiichi Sankyo INC. | $336.10 | 2019-2024 | Injectafer |
| Gilead Sciences, INC. | $268.37 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $257.78 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $203.19 | 2021-2024 | Dificid |
| Qol Medical, LLC | $192.77 | 2021-2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $179.99 | 2020-2024 | Linzess |
| Braintree Laboratories, INC. | $149.06 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $140.94 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $128.75 | 2021-2024 | Resolution 360 Clip |
| W. L. Gore & Associates, INC. | $128.45 | 2025 | Gore Enform Preperitoneal Biomaterial |
| Regeneron Healthcare Solutions, INC. | $118.25 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $118.09 | 2021 | |
| Celgene Corporation | $113.28 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $108.17 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $99.20 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $92.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $79.69 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $78.01 | 2021-2022 | |
| Shire North American Group INC | $72.56 | 2019 | |
| Intuitive Surgical, INC. | $71.98 | 2021-2022 | |
| Dova Pharmaceuticals | $68.69 | 2019 | |
| Aimmune Therapeutics, INC. | $45.72 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $31.62 | 2020-2023 | Rebyota |
| Olympus America INC. | $27.76 | 2022 | |
| Sandoz INC. | $24.15 | 2025 | Hyrimoz |
| Intra-Sana Laboratories | $20.42 | 2022 | |
| Medtronic, INC. | $19.99 | 2025 | Interstim |
| Mallinckrodt Hospital Products INC. | $19.88 | 2023 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $16.99 | 2019 | |
| Capsovision, INC. | $16.34 | 2025 | Capsocam Plus |
| Novo Nordisk INC | $14.94 | 2025 | Wegovy, Saxenda |
| Micro-Tech Endoscopy USA, INC. | $12.63 | 2021 | |
| Alfasigma USA, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Threadgill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.